Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of lymphoma (non-Hodgkin lymphoma) that has come back or not responded to standard treatments.
- You have at least one tumor or lymph node that can be seen on scans.
- You are generally well enough to be up and about for at least part of the day (ECOG score 0, 1, or 2).
- Your major organs (like heart, liver, kidneys, and blood cells) are working well enough for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
This trial is testing an investigational drug called HP-002 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatment. The study aims to see if HP-002 is safe and effective, offering a new option for patients who have limited choices.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.